Clinical Significance of p16 Protein Expression Loss and Aberrant p53 Protein Expression in Pancreatic Cancer
1
조회
0
다운로드
0
인용
0
참고문헌
초록
Abstract
Pancreatic cancer is a disease with poor prognosis mainly due to low resection rates and late diagnosis. To increase resectability and improve survival rates, a better understanding of pancreatic cancer pathogenesis and more effective screening techniques are required. New methods, such as genetic and molecular alterations, may suggest novel approaches for pancreatic cancer diagnosis and treatment. We immunohistochemically investigated 44 formalin-fixed, paraffin-embedded specimens of pancreatic ductal adenocarcinoma using monoclonal anti-p16 antibodies and monoclonal anti-p53 antibodies. The expressions of p16 and p53 proteins were compared using the Chi-square test with SPSS. Disease-free survival was analyzed using the Kaplan-Meier method, verified by the Log- Rank test. Loss of p16 expression was noted in 20 (45.5%) cases and aberrant p53 protein expression was detected in 14 (31.8%) cases. Loss of p16 expression was associated with a higher incidence of lymph node metastasis (p=0.040) and a more advanced stage (p=0.015), although there was no significant correlation between p16 expression and survival. Aberrant p53 protein expression correlated with histologic grade (p= 0.038). Disease-free survival rate was significantly lower in the aberrant p53 protein positive group compared to the negative group (p=0.029). From our results, we suggest that p53 is not a prognostic factor; however, p16 and p53 genes do play important roles in the progression of pancreatic ductal adenocarcinoma.
참고문헌 (28)
- "Annual Report of the Central Cancer Registry in Korea (1997.1.1-1997.12.31)", pp.1~ (1999)
- "Pancreatic cancer", 36, pp.59~152 (1999)
- "The current status of the Whipple operation for periampullary carcinoma", pp.21~49
- "Standards for pancreatic resection in the 1990s", 130, pp.295~300 (1995)
- "Expression of biliary antigen and its clinical significance in hepatocellular carcinoma", 40, pp.472~7 (1999)
- "Frequent somatic mutations and homozygous deletions of the p16 gene in pancreatic adenocarcinoma", pp.27~32
- "p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions", 54, pp.3025~33 (1996)
- "Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas", 56, pp.5360~4 (1996)
- "Tumor-suppressive pathways in pancreatic carcinoma", 57, pp.1731~4 (1997)
- "Deletion and mutation analyses of the p16", MTS1 tumor suppressor gene in human ductal pancreatic cancer reveals a higher frequency of abnormalities in tumor derived cell lines than in primary ductal adenocarcinomas, 1996, pp.56, 1137~41
- "Frequent loss of p16 expression and its correlation with clinicopathological parameters in pancreatic carcinoma", 3, pp.1473~7 (1997)
- "K-ras oncogene subtype mutations are associated with survival but not expression of p53, p16INK4A, p21WAF-1, cyclin D1, erbB-2 and erbB-3 in resected pancreatic ductal adenocarcinoma", 89, pp.469~1 74 (2000)
- "p16 and K-ras gene mutations in the intraductal precursors of human pancreatic adenocarcinoma", 57, pp.2140~3 (1997)
- "Inactivation of the p6 tumor-suppressor gene in pancreatic duct lesions loss of intranuclear expression", 58, pp.4740~4 (1998)
- "Reduced survival inpatients with ductal pancreatic adenocarcinomas associated with CDKN2 mutation", 88, pp.680~2 (1996)
- "Prognosis of human pancreatic adenocarcinoma review of clinical and histopathological variables and possible uses of new molecular methods", 165, pp.292~306 (1999)
- "Molecular biology of pancreatic cancer; oncogenes, tumour suppressor genes, growth factors, and their receptors from a clinical perspective", 26, pp.29~52 (2000)
- "Prevalence and clinical significance of combined K-ras mutation and p53 aberration in pancreatic adenocarcinoma", 21, pp.127~43 (1997)
- "Molecular pathology of primary and metastatic ductal pancreatic lesions", 79, pp.700~16 (1997)
- "Prognostic significance of molecular alterations in human pancreatic carcinoma-an immunohistological study", 383, pp.152~5 (1998)
- "Expression of Bcl-2 and p53 protein inresectable invasive ductal carcinoma of the pancreas effects on clinical outcome and efficacy of adjuvant chemotherapy", 76, pp.188~96 (2001)
- "Association of p53 gene mutations with short survival in pancreatic adenocarcinoma", 86, pp.174~81 (1995)
- "p53 overexpression in lymph node metastases predicts clinical outcome in ductal pancreatic cancer", 19, pp.26~32 (1999)
- "Hereditary factors in pancreatic cancer", 9, pp.12~31 (2002)
- "Immunohistochemical analysis of p53 expression in human pancreatic carcinomas", pp.150~4
- "P53 expression in human pancreatic cancer correlates with enhanced biological aggressiveness", pp.2477~83
- "Pancreas Club Meeting California", 173, pp.153~8 (1997)
- "Frequent codeletion of p16", MTS1 and p15, MTS1 in pancreatic tumors, 1996[DOI]